Intec reaches deal with LTS Lohmann to manufacture its Parkinson’s drug candidate

Parkinson's brain cell
A Lewy body in a brain cell of the substantia nigra in Parkinson's disease. (By Marvin 101 (Own work) [CC BY-SA 3.0 (], via Wikimedia Commons)

Intec Pharma, the maker of the Accordion delivery platform, is partnering with LTS Lohmann Therapie-Systeme of Germany to manufacture its lead drug candidate Accordion Pill carbidopa/levodopa, designed to treat severe symptoms in advanced cases of Parkinson’s disease.

Israel-based Intec is currently manufacturing the drug at its facility in Jerusalem. Under terms of the partnership, LTS will produce the AP-CD/LD capsules at its facility in Andernach, Germany, once the production line is completed, the company said. Financial terms of the partnership weren’t disclosed.

“This is a key achievement for Intec as we near completion of our pivotal Phase 3 Accordance clinical trial in advanced Parkinson's Disease patients and advance our pre-commercial strategies for AP-CD/LD," Jeffrey Meckler, Intec’s chief executive, said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Intec’s Accordion platform is a gastroretentive delivery system designed to improve the absorption of poorly soluble drugs in the gastrointestinal tract. The technology incorporates a biodegradable polymeric film folded into a regular capsule. When released, the structure unfolds into an accordion shape and can be retained in the stomach for up to 12 hours, releasing the contained drug there in a more controlled manner than by oral consumption alone.

RELATED: Intec pulls in $5.2M Israeli grant for Parkinson's oral candidate

In addition to the Parkinson’s candidate, which delivers a combination of carbidopa and levodopa to treat symptoms of the neurological disorder, Intec has also been working on a candidate to treat insomnia and one for treating ulcers in the bowel.

Suggested Articles

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.

Turkey is getting its first locally produced mAb via an Iranian biosimilars marker and the $100 million plant it built there.

Teva is recalling 10 more lots of losartan as blood pressure drugs tainted with suspected carcinogens continue to pop up in the U.S. supply chain.